Renal Cell Carcinoma   

Questions discussed in this category


For patients who have progressed on first line checkpoint inhibitor (e.g. Nivo/Ipi) and second line TKI (e.g. Cabozantinib) 

What systemic therapy options are available for ESRD patients?

If so, how would you design and deliver the treatment?

For example, is there any data to suggest a benefit to starting with immunotherapy prior to TKI or the alternative?

Some considerations: -Cabozantinib (Based on CABOSUN trial, NCCN does not list this as a Category 1 recommendation)-Nivolumab + Ipilimumab (CheckMate...

Is there any specific precautions or concerns to consider with TKI initiation if the patient has vasogenic edema?

(assuming that the patient is int-poor risk, has measurable disease outside of the CNS, warrants treatment with appropriate PS)

There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you u...

NCCN include active surveillance as an option in specific circumstances based on Rini et al. (Lancet Oncology 2016) however this set is not well defin...

Wouldn't lymph node dissection improve sensitivity of staging and inform adjuvant treatment decisions?

Are there any patient and/or pathologic features that would lend you to considering IL-2 over other approved I/O or TKI therapies?

I have seen the question regarding treatment of non-clear cell RCC in general: https://www.themednet.org/question/3934. Is there any data or experienc...

Most of the studies have excluded non clear cell histologies. If you use a similar approach to clear cell, have you seen similar responses?

What are the special considerations in the non-metastatic setting vs metastatic setting?

Recent evidence has been mixed, with no DFS or OS benefit in 1 trial (ASSURE, Haas et al, Lancet 2016) and DFS benefit in another (S-TRAC, Ravaud et a...

The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib. 

In the setting of recent craniotomy and a plan for SRS to the surgical cavity, which systemic therapy would you choose and when would you&nb...

Are there circumstances when you would choose IL-2 over checkpoint inhibitor trials or TKIs for fit patients? How should IL-2 be sequenced with these ...

For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in thi...


Papers discussed in this category


Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-02-01

Journal for immunotherapy of cancer, 2015

Cancer immunology, immunotherapy : CII, 2016-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995-03

The cancer journal from Scientific American, 2000-02

Cancer immunology, immunotherapy : CII, 2016-12

Urologic oncology, 2015-11

Lancet (London, England), 2016-05-14

The New England journal of medicine, 2016-12-08

JAMA oncology, 2017-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

American journal of clinical oncology, 1991-04

Annals of surgical oncology, 2018-07

Cancer,

J Clin Endocrinol Metab, 2006 Aug 08

J Cancer Res Ther,

J Clin Endocrinol Metab,

N. Engl. J. Med., 2018 Jun 03

The New England journal of medicine, 2019-03-21

The Lancet. Oncology, 2016-03

European urology, 2016-05

Clinical genitourinary cancer, 2017-12

Journal for immunotherapy of cancer, 2018-01-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-04

The New England journal of medicine, 2018-04-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

European urology focus, 2019-11

Clinical genitourinary cancer, 2017-02

Journal of immunotherapy (Hagerstown, Md. : 1997), 2014-04

Journal for immunotherapy of cancer, 2019-02-18

Journal of clinical pharmacology, 2010-04

BJU Int, 2011 Oct

Anticancer Drugs,